ResearcherFirst Hospital of China Medical UniversityNo recent work listed

Shuangning Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-1164-303X; OpenAlex author ID A5074023575. Sources: OpenAlex.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2017: 1 paper

Papers 1

Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Last author DOI 10.1038/cddis.2017.547 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guosen Wang · 1 shared paper, 2017 · strength 0.07
- Paper Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. DOI 10.1038/cddis.2017.547 ↗
Song He · 1 shared paper, 2017 · strength 0.07
- Paper Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. DOI 10.1038/cddis.2017.547 ↗
Weiwei Sheng · 1 shared paper, 2017 · strength 0.07
- Paper Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. DOI 10.1038/cddis.2017.547 ↗
Ming Dong · 1 shared paper, 2017 · strength 0.07
- Paper Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. DOI 10.1038/cddis.2017.547 ↗
Jianping Zhou · 1 shared paper, 2017 · strength 0.07
- Paper Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. DOI 10.1038/cddis.2017.547 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.